*By Bridgette Webb*
Drugmaker Merck announced earlier this month it will slash prices on several drugs by 10 percent or more.
But there is a catch: the price rollback will only affect some of the smaller products in its portfolioーlike Hepatitis C drug, Zepatier, which accounts for about 4 percent of the company's salesーand not top sellers like cancer treatment Keytruda.
"Their scope is relatively limited," said Peter Loftus, a Reporter for the Wall Street Journal, during an interview on Cheddar Monday. "If you think about the total sales that Merck generatesーit's a relatively small percentage."
Merck's announcement was met with praise from the Trump administration. Health and Human Services Secretary Alex Azar claimed the drop in prices was spurred by Trump's latest crackdown on pharmaceutical companies.
Other big pharma names are following suit: Pfizer and Novartis announced they will freeze price increases for the rest of the year, earning them congratulatory tweets from the president.
Despite all of the price freezes and drops, Loftus says that patients may not actually see any real savings.
"I don't think you can say on a widespread basis, and really for the average drug or patient, that prices are coming down, there are still price increases."
For the full segment, [click here.]
(https://cheddar.com/videos/drugmakers-tout-lower-prices)
U.S. health regulators on Monday approved a new easy-to-use version of a medication to reverse overdoses caused by fentanyl and other opioids driving the nation’s drug crisis.
Millions of Americans are impacted by mental health issues and a growing number of them are teenagers, causing concerns for parents across the country. Psychiatrist Dr. Liat Jarkon spoke with Cheddar News about how parents can have open and honest conversations with their kids.
A new study shows that climate change is making it harder to fall asleep. The study, published in Cell Press over the weekend, shows that millions of people are already sleeping less because of higher overnight temperatures.
The natural burst of El Nino warming that changes weather worldwide is far costlier with longer-lasting expenses than experts had thought, averaging trillions of dollars in damage, a new study found.
